Hem › Steatotisk leversjukdom › Maryland
Kliniska studier för Steatotisk leversjukdom i Maryland
8 studier för Steatotisk leversjukdom söker deltagare vid platser i Maryland.
Städer i Maryland
Officiell studietext (engelska)
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 5 okt. 2026 · NCT06318169A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Mercy Medical Center - Baltimore, Baltimore
- Capital Digestive Care - Chevy Chase, Chevy Chase
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Baltimore
- Akero Clinical Study Site, Bethesda
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 21 sep. 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Mid-Atlantic GI Research, Greenbelt
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 9 sep. 2026 · NCT07288138Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- National Institutes of Health Clinical Center, Bethesda
RekryterarFas 2Friska volontärer välkomna
Ålder 18 till 100 · Alla kön · Uppdaterad 10 aug. 2026 · NCT03884075Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
- National Institutes of Health Clinical Center, Bethesda
RekryterarFas 1Friska volontärer välkomna
Ålder 21 till 65 · Alla kön · Uppdaterad 20 juli 2026 · NCT04781322A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Baltimore
RekryterarFas 2
Ålder 18 till 75 · Alla kön · Uppdaterad 8 juli 2026 · NCT06920043Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.